|
|
Adenovirus |
| Table of Contents |
- General Information
- NCBI Taxonomy ID
- Disease
- Introduction
- Vaccine Related Pathogen Genes
- exa
- M gene
- Vaccine Information
- Adenovirus Type 3, 7, and 55 Vaccine rAdMHE3-55
- Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
- References
|
| I. General Information |
| 1. NCBI Taxonomy ID: |
|
10508 |
|
2. Disease: |
| Respiratory infection |
|
3. Introduction |
| Adenoviruses are a large group of DNA viruses with a distinguished experimental history, including contributions to the discovery of RNA splicing and the elucidation of central pathways in cell transformation. Some adenoviruses are human pathogens. They are also very much in vogue as potential vaccine and gene therapy vectors. Structure-based redesign of their cell-targeting and antigenic properties is therefore a desirable goal (Harrison, 2010). |
| II. Vaccine Related Pathogen Genes |
|
1. exa |
|
|
2. M gene |
|
| III. Vaccine Information |
 |
|
 |
|
|
|
|
1. Adenovirus Type 3, 7, and 55 Vaccine rAdMHE3-55 |
| a. Type: |
| Recombinant vector vaccine |
| b. Status: |
| Research |
| c. Host Species for Licensed Use: |
| None |
| d. Antigen |
| HAdV3 hexon protein, HAdV7 hexon protein, HAdV55 hexon protein (Liu et al., 2018) |
| e. Vector: |
| Plasmids pBRAd-MHE3 and pSKE3LR-h55 were each cloned by using ClonExpress Entry One Step Cloning Kit and then co-transfected into Top 10 cells. Through homologous recombination, Fragment h55 from pSKE3LR-h55 was integrated into pBRAd-MHE3, the resulting trivalent virus vector was named pBRAd-MHE3-h55. (Liu et al., 2018) |
| f. Immunization Route |
| Intramuscular injection (i.m.) |
| g. Description |
| A trivalent recombinant vector adenovirus vaccine composed of L3 epitopes from HAdV3, HAdV7, and HadV55. (Liu et al., 2018) |
| h.
Mouse Response |
- Vaccination Protocol:
Female BALB/c mice were divided into two groups: animals in group vaccinated received rAdMHE3-h55 vaccination, whereas animals in group unvaccinated were only infected with viruses without vaccination. Group vaccinated was further subdivided into the vaccination-challenge group and vaccination-unchallenged group, the latter was served as a control. Mice in group vaccinated were first vaccinated intramuscularly four times with 1X 10^10 genome copies of recombinant virus rAdMHE3-h55at 2-week intervals. (Liu et al., 2018)
- Immune Response:
To verify the immunizing potential of the recombinant adenovirus rAdMHE3-h55, we immunized BALB/c mice with three doses of 5 X 10^9 VPs of rAdMHE3-h55. Sera were collected from the mice after the third immunization. Purified adenoviruses of HAdV-55, rAdMHE3, or rAdMHE3-h55 were subjected to western blot analyses with the mouse antisera. For all three adenoviruses, a hexon protein-like band of approximately 120 kDa were detected by anti-rAdMHE3-h55. ELISAs were used to further analyze the antisera from mice immunized with rAdMHE3-h55. The results showed that the mouseanti-rAdMHE3-h55 gave strong responses against HAdV-3, HAdV-7, HAdV-55 and rAdMHE3-h55. These findings confirmed that the recombinant adenovirus rAdMHE3-h55 was able to induce an immune response in mice and the antibodies possessed different neutralizing capabilities against HAdV-3, HAdV-7, and HAdV-55. (Liu et al., 2018)
- Challenge Protocol:
Two weeks after the fourth vaccination, mice in the vaccination-challenge group and unvaccinated group, with five or eight mice per time-point, were inoculated intranasally with 50 lL (about 2X 10^11 genome copies) of live HAdV-3, HAdV-7H, or AdV-55. Same number of naïve mice at each time point was served as negative control. Mice were euthanized on post-challenge day 1, 3, or 5.(Liu et al., 2018)
- Efficacy:
In order to verify the protective effect of rAdMHE3-h55 vaccination, the respiratory system of the infected mice was examined because this was the target site of the HAdV infection. On post-challenge day 1, 3, or 5, mice were euthanized and their lung tissues were collected. Replication of HAdV-3, HAdV-7 and HAdV-55 in the lung tissues was detected by Q-PCR. There were statistically significant differences in the genome copies between vaccination-challenge group and un-vaccination group by day 5: HAdv-3 (p < 0.01, Mann- Whitney test), HAdV-7 (p < 0.05, Mann-Whitney test), HAdV-55 (p < 0.05, Mann-Whitney test). These data indicated that immunization of BALB/c mice with the recombinant trivalent virus AdMHE3-h55could protect animals simultaneously from infections byHAdV-3, HAdV-7, or HAdV-55.(Liu et al., 2018)
|
|
|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
2. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral |
| a. Product Name: |
| Adenovirus Type 4 and Type 7 Vaccine, Live, Oral |
| b. Manufacturer: |
| Barr Labs, Inc. |
| c. Vaccine Ontology ID: |
| VO_0000096 |
| d. CDC CVX code: |
| 143 |
| e. Type: |
| Live vaccine |
| f. Status: |
| Licensed |
| g. Location Licensed: |
| United States |
| h. Host Species for Licensed Use: |
| Human |
| i. Preparation |
| Virus is prepared in human-diploid fibroblast cell cultures (strain WI-38). The virus strains have not been attenuated. The virus is harvested and dried. The dry virus material includes monosodium glutamate, sucrose, D-mannose, D-fructose, dextrose, human serum albumin, potassium phosphate and plasdone C (FDA: Adenovirus Vaccine). |
| j. Immunization Route |
| orally |
| k. Storage |
| Store refrigerated between 2° and 8° C (35° and 46° F). Do not freeze (FDA: Adenovirus Vaccine). |
| l . Approved Age for Licensed Use |
| Approved for use in military populations 17-50 years of age (FDA: Adenovirus Vaccine). |
| m. Contraindication |
| Pregnancy, allergy to vaccine components, or inability to swallow tablets whole (FDA: Adenovirus Vaccine). |
| n. Description |
| Indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7, virus strains have not been attenuated. The vaccine is composed of two tablets (one of Adenovirus type 4 and one Adenovirus type 7) designed to pass intact through the stomach and release the live virus in the intestine (FDA: Adenovirus Vaccine). |
|
|
|
|
|
|
|
|
| IV. References |
1. Baden et al., 2014: Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH. First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). The Journal of infectious diseases. 2014; ; . [PubMed: 24719474].
2. FDA: Adenovirus Vaccine: FDA: Adenovirus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm247508.htm]
3. Harrison, 2010: Harrison SC. Virology. Looking inside adenovirus. Science (New York, N.Y.). 2010; 329(5995); 1026-1027. [PubMed: 20798308].
4. Kim et al., 2014: Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. Journal of virology. 2014; 88(9); 5100-5108. [PubMed: 24574396].
5. Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].
|
|
